1-20 of 21
Sylvia Herter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Jenny Thom, Sylvia Herter, Guy Georges, Koorosh Korfi, Martin Lechmann, Miro Julian Eigenmann, Daniel Marbach, Candice Jamois, Katharina Lechner, Sreenath M. Krishnan, Brenda Gaillard, Joana Marinho, Sven Kronenberg, Leo Kunz, Sabine Wilson, Stefanie Briner, Samuel Gebhardt, Ahmet Varol, Birte Appelt, Valeria Nicolini, Dario Speziale, Miriam Bez, Esther Bommer, Jan Eckmann, Carina Hage, Florian Limani, Silvia Jenni, Anne Schoenle, Marine Le Clech, Jean-Baptiste Pierre Vallier, Sara Colombetti, Marina Bacac, Stephan Gasser, Christian Klein, Pablo Umaña
Journal: Blood
Blood (2024) 143 (21): 2152–2165.
https://doi.org/10.1182/blood.2023023381
Published: 2024
Includes: Supplemental data
Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Clinical Trials & Observations Brief Report
Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay
Journal: Blood
Blood (2024) 143 (1): 57–63.
https://doi.org/10.1182/blood.2023020554
Published: 2024
Includes: Supplemental data
Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Koorosh Korfi, Ailsa Christiansen, Zhiwen Jiang, Sabine Wilson, Samuel Tracy, Annika Blank, Sylvia Herter, Natalie Dimier, Bruno Gomes, Pablo Umana, Herve Ghesquieres, Roch Houot, Fritz Offner, Harriet Walter, Nancy L. Bartlett, Guillaume Cartron, Michael Dickinson, William Townsend, Giuseppe Gritti, Francesc Bosch Albareda, Franck Morschhauser, Martin Hutchings, Carmelo Carlo-Stella, Katharina Lechner
Journal: Blood
Blood (2023) 142 (Supplement 1): 3017.
https://doi.org/10.1182/blood-2023-173677
Published: 2023
Journal Articles

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Giulia Petra Rappa, Monika Sponheimer, Gerulf Hänel, Anne-Sophie Neumann, Nora Philipp, Koorosh Korfi, Sylvia Herter, Johannes Sam, Franz Schuler, Christian Klein, Marina Bacac, Pablo Umana, Marion Subklewe
Journal: Blood
Blood (2023) 142 (Supplement 1): 2058.
https://doi.org/10.1182/blood-2023-180785
Published: 2023
Journal Articles

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Sina Nassiri, Stephan Schmeing, Gabrielle Leclercq, Sylvia Herter, Llucia Alberti Servera, Tamara Hüsser, Emilio Yángüez, Diana Dunshee, Koorosh Korfi, Pablo Umana, Ann-Marie E. Bröske, Alessia Bottos, Marina Bacac
Journal: Blood
Blood (2023) 142 (Supplement 1): 1619.
https://doi.org/10.1182/blood-2023-179776
Published: 2023
Journal Articles

Pharmacologic Inhibitors of STAT3 or BCL6 Transcriptional Function Sensitize Lymphoma Cells to the Novel PD-1 Cis-Targeted PD1-IL2v Immunocytokine in a Murine Model

Weiyuan Wang, Foster Burton, Sylvia Herter, Laura Codarri Deak, Christian Klein, David Frank
Journal: Blood
Blood (2022) 140 (Supplement 1): 8835–8836.
https://doi.org/10.1182/blood-2022-167853
Published: 2022
Journal Articles

RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Sylvia Herter, Guy Georges, Jenny Tosca Thom, Leo Kunz, Samuel Gebhardt, Florian Limani, Stefanie Briner, Silvia Jenni, Anne Schönle, Marine Le Clech, Ahmet Varol, Esther Bommer, Birte Appelt, Sara Colombetti, Stephan Gasser, Marina Bacac, Christian Klein, Pablo Umana
Journal: Blood
Blood (2022) 140 (Supplement 1): 3142–3143.
https://doi.org/10.1182/blood-2022-159941
Published: 2022
Journal Articles

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, Carmelo Carlo-Stella, Giuseppe Gritti, Francesc Bosch, Franck Morschhauser, William Townsend, Fritz Offner, Harriet S Walter, Herve Ghesquieres, Roch Houot, Guillaume Cartron, Natalie Dimier, Stephen Fowler, Emma Harrop, Sylvia Herter, Abiraj Keelara, Koorosh Korfi, Jeff Luong, Claudia Mueller, Robert Nutbrown, Giuseppe Palldino, Matt Whayman, Isabel Prieto, Sarah Louise Mycroft, Daria Rukina, Katharina E Lechner, Michael Dickinson
Journal: Blood
Blood (2022) 140 (Supplement 1): 9461–9463.
https://doi.org/10.1182/blood-2022-157011
Published: 2022
Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40.
https://doi.org/10.1182/blood-2020-134782
Published: 2020
Journal Articles

Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Martin Hutchings, MD PhD, Fritz C. Offner, MD PhD, Francesc Bosch, MD PhD, Giuseppe Gritti, MD PhD, Carmelo Carlo-Stella, MD, Harriet Walter, William Townsend, MRCP,MDFRCPath, Franck Morschhauser, MD PhD, Guillaume Cartron, MD PhD, Hervé Ghesquieres, MD PhD, Sophie de Guibert, MD, Sylvia Herter, PhD, Koorosh Korfi, PhD, Veronica Craine, Sarah Louise Mycroft, Matt Whayman, Claudia Mueller, Natalie Dimier, PhD, Tom Moore, MBChB, Sara Belli, Martin Kornacker, MD, Katharina Lechner, Michael Dickinson, DMed Sci
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-136571
Published: 2020
Journal Articles

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Clinical Trials & Observations
Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, Carla Casulo, Steven Le Gouill, Laurie H. Sehn, Herve Tilly, Guillaume Cartron, Martine E. D. Chamuleau, Andre Goy, Constantine S. Tam, Pieternella J. Lugtenburg, Adam M. Petrich, Arijit Sinha, Divya Samineni, Sylvia Herter, Ellen Ingalla, Edith Szafer-Glusman, Christian Klein, Deepak Sampath, Martin Kornacker, Mehrdad Mobasher, Franck Morschhauser
Journal: Blood
Blood (2019) 133 (18): 1964–1976.
https://doi.org/10.1182/blood-2018-11-880526
Published: 2019
Includes: Supplemental data
Journal Articles

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac, PhD, Pablo Umaña, PhD, Sylvia Herter, PhD, Sara Colombetti, PhD, Johannes Sam, PhD, Marine Le Clech, Anne Freimoser-Grundschober, PhD, Marine Richard, Valeria Nicolini, PhD, Christian Gerdes, PhD, Laurent Lariviere, PhD, Christiane Neumann, PhD, Christian Klein, PhD
Journal: Blood
Blood (2016) 128 (22): 1836.
https://doi.org/10.1182/blood.V128.22.1836.1836
Published: 2016
Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD
Journal: Blood
Blood (2014) 124 (21): 3342.
https://doi.org/10.1182/blood.V124.21.3342.3342
Published: 2014
Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1765.
https://doi.org/10.1182/blood.V124.21.1765.1765
Published: 2014
Journal Articles

Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity

Frank Herting, PhD, Sylvia Herter, PhD, Thomas Friess, PhD, Christian Lehmann, PhD, Marina Bacac, PhD, Markus Dangl, PhD, Christian Klein, PhD
Journal: Blood
Blood (2014) 124 (21): 1780.
https://doi.org/10.1182/blood.V124.21.1780.1780
Published: 2014
Journal Articles

Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies

Deepak Sampath, PhD, Sylvia Herter, PhD, Frank Herting, Ellen Ingalla, Michelle Nannini, Marina Bacac, Wayne J. Fairbrother, PhD, Christian Klein, PhD
Journal: Blood
Blood (2013) 122 (21): 4412.
https://doi.org/10.1182/blood.V122.21.4412.4412
Published: 2013
Journal Articles

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

Sylvia Herter, PhD, Christian Klein, PhD, Pablo Umana, PhD, Marina Bacac
Journal: Blood
Blood (2013) 122 (21): 5136.
https://doi.org/10.1182/blood.V122.21.5136.5136
Published: 2013
Journal Articles

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Christian Klein, PhD, Inja Waldhauer, PhD, Valeria Nicolini, PhD, Claire Dunn, PhD, Anne Freimoser-Grundschober, PhD, Gerrits Danny, PhD, Otto Boerman, PhD, Tapan Nayak, PhD, Sylvia Herter, PhD, Erwin Van Puijenbroek, Oliver Ast, PhD, Thomas Hofer, PhD, Ralf Hosse, Sabine Lang, Sebastian Neumann, Hubert Kettenberger, Markus Neubauer, Ingo Gorr, Dietrich Tuerck, Stefan Evers, Christian Gerdes, Victor Levitsky, Marina Bacac, Ekkehard Moessner, Pablo Umana, PhD
Journal: Blood
Blood (2013) 122 (21): 2278.
https://doi.org/10.1182/blood.V122.21.2278.2278
Published: 2013
Journal Articles

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs . the Type I CD20 Antibodies Rituximab and Ofatumumab

Sylvia Herter, Inja Waldhauer, Tina Otz, Frank Herting, Sabine Lang, Valeria Nicolini, Michaela Römmele, Thomas Friess, Erwin Van Puijenbroek, Marina Bacac, K. Michael Weidner, PhD, Christian Gerdes, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2010) 116 (21): 3925.
https://doi.org/10.1182/blood.V116.21.3925.3925
Published: 2010
Journal Articles

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser, Ursula Püntener, Carla Schmidt, Sylvia Herter, Roger Grau, Christian Gerdes, Adam Nopora, Erwin van Puijenbroek, Claudia Ferrara, Peter Sondermann, Christiane Jäger, Pamela Strein, Georg Fertig, Thomas Friess, Christine Schüll, Sabine Bauer, Joseph Dal Porto, Christopher Del Nagro, Karim Dabbagh, Martin J. S. Dyer, Sibrand Poppema, Christian Klein, Pablo Umaña
Journal: Blood
Blood (2010) 115 (22): 4393–4402.
https://doi.org/10.1182/blood-2009-06-225979
Published: 2010